Persistence of antibodies six years after priming immunisation with Meningococcal C conjugate vaccine and response to the Hib-MenC (Menitorix®) vaccine in healthy children

ISRCTN ISRCTN72858898
DOI https://doi.org/10.1186/ISRCTN72858898
Secondary identifying numbers OVG 2006/2
Submission date
06/07/2006
Registration date
04/09/2006
Last edited
28/07/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr Andrew Pollard
Scientific

Centre for Vaccinology and Tropical Medicine
Churchill Hospital
Oxford
OX3 7LJ
United Kingdom

Study information

Study designPhase IV single-centre open-label trial
Primary study designInterventional
Secondary study designSingle-centre
Study setting(s)Not specified
Study typePrevention
Scientific titleA phase IV, single centre, open-label study to investigate the persistence of antibodies six years after priming immunisation with Meningococcal C conjugate vaccine and induction of long term immunological memory by assessing persistence of memory B cells and response to the Hib-MenC (Menitorix®) vaccine, in healthy children six to 12 years of age
Study objectivesTo asess the persistence of antibodies, six years after priming immunisation with Meningococcal C conjugate vaccine and response to the Hib-MenC (Menitorix®) vaccine.

Please note that the following amendments have been made to this trial record as of 16/03/2009:
1. The public title has been changed from "A phase IV, single centre, open-label study to investigate the persistence of antibodies six years after priming immunisation with Meningococcal C conjugate vaccine and induction of long term immunological memory by assessing persistence of memory B cells and response to the Hib-MenC (Menitorix®) vaccine, in healthy children six to 12 years of age" to "Persistence of antibodies six years after priming immunisation with Meningococcal C conjugate vaccine and response to the Hib-MenC (Menitorix®) vaccine in healthy children". The original public title has been moved to the scientific title field.
2. The sponsor name has been amended from John Radcliffe Hospital (UK) to University of Oxford (UK) (due to incorrect sponsor name provided at time of registration).
Ethics approval(s)Favourable opinion granted from Oxfordshire LREC B on 13 July 2006.
Health condition(s) or problem(s) studiedMeningococcal C and Haemophilus influenzae type B diseases
InterventionAll 250 participants will receive one dose of the Hib-MenC (Menitorix®) conjugate vaccine. Blood samples will be taken at zero, one and 12 months after the vaccine. In 75 participants only, blood will also be taken on day seven.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase IV
Drug / device / biological / vaccine name(s)Menitorix®; (Haemophilus influenzae B [Hib] and Meningococcal C[MenC]) vaccine
Primary outcome measureSerum bactericidal antibody to meningococcal serogroup C six years after priming immunisation.
Secondary outcome measures1. Measurement of antibody and B cell responses and assessment of memory induction following the Hib-MenC (Menitorix®) vaccine
2. Number and nature of any adverse events occuring during the study
Overall study start date14/08/2006
Completion date16/06/2008

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit6 Years
Upper age limit12 Years
SexBoth
Target number of participants250
Key inclusion criteria1. Participant‘s parent or legally authorised representative is willing and able to give written informed consent for participation after the nature of the study has been explained
2. Male or Female, aged six years (+ zero days) to 12 years (+ 364 days) on the day of enrolment
3. In good health as determined by:
3.1. medical history
3.2. pre-vaccination check performed by a physician if indicated by history
3.3. clinical judgment of the investigator
4. Able (in the investigators opinion) and willing to comply with all study requirements including being available for all the visits scheduled in the study
5. Parent or legally authorised representative is willing to allow his or her child’s (the participant’s) General Practitioner to be notified of participation in the study and contacted if required for confirmation of vaccination history
6. Whose parent or legally authorised representative believes to their best knowledge that their child has received all the recommended vaccinations as part of the UK routine childhood immunisation schedule (including Haemophilus influenzae B (Hib) if aged six months to four years in April 2003 (received 4/2003 - 12/2004) and Meningococcal C (MenC) if aged six months to 18 years in Nov 1999 (received 11/1999 - 06/2001) as part of the UK ‘catch up’ vaccination campaigns)
Key exclusion criteria1. Have a history of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component
2. Axillary temperature more than or equal to 38.0°C or presence of any systemic illness on the day of enrolment
3. Have experienced significant acute or chronic infection within the previous seven days or have experienced fever (more than or equal to 38.0°C) within the previous three days
4. Receipt of systemic antibiotics (either oral or parenteral) will delay enrolment until at least 14 days after cessation of antibiotics, with the exception of beta-lactam antibiotics (examples: penicillin, amoxicillin, ceftriaxone, cefuroxime, cephalexin, etc.) who may be enrolled seven days after the last dose
5. Have a previous clinical or bacteriological or suspected diagnosis of meningitis
6. Have a history of household contact or intimate exposure to an individual with culture proven Neisseria meningitis or Hib disease in the previous 60 days
7. Have a present or suspected serious disease such as metabolic, cardiac, autoimmune, endocrine (including insulin dependent diabetes), significant hepatic or renal impairment or progressive neurological impairment
8. Have any immunodeficiency, including use of systemic corticosteroids for more than five days or in a daily dose more than 1 mg/kg/day prednisone or equivalent for less than or equal to five days in the previous 30 days (inhaled high-potency corticosteroids equivalent to budesonide 800 mcg/day or fluticasone 750 mcg/day)
9. Have a genetic anomaly e.g. Down’s syndrome
10. Born after a gestation period of less than 36 weeks or more than 42 weeks
11. Have scheduled elective surgery or other procedures requiring general anaesthesia during the study
12. Have received of any blood, blood products or parenteral immunoglobulin preparation within the past 12 weeks
13. Have received any additional doses of Hib or MenC vaccines in addition to those given in accordance with the UK routine immunisation schedule or ‘catch up’ campaigns
14. Participants who have participated in another research study involving an investigational product in the past 12 weeks or are planning to receive a vaccine or investigational product within the next month
15. Have a known bleeding diathesis or any condition associated with a prolonged bleeding time
16. Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study
Date of first enrolment14/08/2006
Date of final enrolment16/06/2008

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Centre for Vaccinology and Tropical Medicine
Oxford
OX3 7LJ
United Kingdom

Sponsor information

University of Oxford (UK)
Hospital/treatment centre

c/o Ms Heather House
Clinical Trials Office
Manor House
John Radcliffe Hospital
Headington
Oxford
OX3 9DZ
England
United Kingdom

Website http://www.admin.ox.ac.uk/rso/contactus/ctrg.shtml
ROR logo "ROR" https://ror.org/052gg0110

Funders

Funder type

Industry

GSK Biologicals (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 15/06/2010 Yes No